Abstract:The main actions of metformin are as follows: To reduce hyperglycemia via the suppression of gluconeogenesis, improve glucose uptake and insulin sensitivity, and stimulate activation of adenosine monophosphate-activated protein kinase during the treatment of diabetes mellitus. It is well known that metformin acts via complex mechanisms, including multitarget and multipathway mechanisms; however, the multi-targeted antidiabetic genes of metformin remain obscure. The present study aimed to perform transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. The type 2 diabetes rat model was established using streptozotocin. Fasting blood glucose, hemoglobin A1c, serum insulin and biological parameters were subsequently measured. Differentially expressed genes (DEGs) and proteins were identified in the rat livers by expression profile analysis and isobaric tags for relative and absolute quantitation (iTRAQ). A 1.5-fold alteration in gene expression, as determined using chip-based expression profile analysis, and a 1.2-fold alteration in protein expression, as determined using iTRAQ, were considered physiologically significant benchmarks, which were used to identify DEGS in metformin-treated rats with type 2 diabetes mellitus. The DEGs were verified using quantitative polymerase chain reaction (qPCR) and western blot analysis. Numerous hepatic genes involved in various metabolic pathways were affected by metformin; in particular, genes associated with lipid metabolism were markedly affected. Expression profile analysis and iTRAQ analysis suggested that carboxylesterase 1C subunit (Ces1C) and cholesterol 7-hydroxylyase (Cyp7a1) may serve as important DEGs, which were validated by qPCR and western blot analysis. Ces1C and Cyp7a1 are the main enzymes in cholesterol metabolism, yet the result of western blotting was not consistent with qPCR. The present study demonstrated that metformin may affect the expression of numerous hepatic genes involved in metabolic pathways, particularly the lipid and cholesterol metabolic pathways. Ces1C and Cyp7a1 may be considered novel therapeutic target genes in the liver, which are involved in the antidiabetic effects of metformin.

Genomic Characterization of Metformin Hepatic Response

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Metformin Pharmacogenomics: a Genome-Wide Association Study to Identify Genetic and Epigenetic Biomarkers Involved in Metformin Anticancer Response Using Human Lymphoblastoid Cell Lines.

The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection

Exploring metformin monotherapy response in Type-2 diabetes: Computational insights through clinical, genomic, and proteomic markers using machine learning algorithms

Cellular and molecular mechanisms of metformin: an overview

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Multi-Omics Analysis Revealed the rSNPs Potentially Involved in T2DM Pathogenic Mechanism and Metformin Response

Metformin Transporter Pharmacogenomics: Insights into Drug Disposition—where Are We Now?

The Effect of Metformin Treatment on the Circulating Proteome

The Role of ATM in Response to Metformin Treatment and Activation of AMPK.

New Insights Into the Genetics of Glycemic Response to Metformin

Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients

Metformin and Metabolic Diseases: a Focus on Hepatic Aspects.

Data-dependent and -independent acquisition lipidomics analysis reveals the tissue-dependent effect of metformin on lipid metabolism

The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application

Impact of SLC22A1 rs12208357 on therapeutic response to metformin in type 2 diabetes patients

Cellular Responses to the Metal-Binding Properties of Metformin